AT-121
Smoking Cessation / Abstinence; Pain
Phase 1Active
Key Facts
About Astraea Therapeutics
Astraea Therapeutics is a privately-held, clinical-stage biotech founded in 2008 (not 2018 as in some records) and based in Mountain View, California. The company is advancing a pipeline of oral medicines targeting addiction to opioids, nicotine, and psychostimulants, with a core platform built on novel target validation in the neurobiology of relapse. Led by founder and CSO Dr. Nurulain Zaveri, Astraea's most advanced asset, AT-121, has demonstrated promising preclinical data for analgesia without addiction liability and is advancing into clinical development for smoking cessation. The company operates with a virtual or lean team model, leveraging external consultants for key development functions.
View full company profile